OR WAIT null SECS
Here's a preview of what to expect this week from Contemporary OB/GYN®.
Every October, the pink ribbons and flamingoes come out to raise breast cancer awareness. However, Pink October should go beyond breast cancer awareness to shine the light on women’s health overall, and, as important, the huge responsibility women bear as chief decision-makers for their families’ health care.
The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.
Check back soon for additional updates.